Eisai seeks to market Gasmotin in Thailand

Published: 29-Jun-2007
Regulatory

Drug improves digestive functions and treats symptoms of heartburn, nausea and vomiting


Japan-based Eisai Co has asked the Thai authorities for permission to market Gasmotin, a drug that improves digestive functions and treats symptoms of heartburn, nausea and vomiting associated with chronic gastritis.

Gasmotin was developed by Dainippon Sumitomo Pharma, but Eisai obtained the marketing rights to 10 countries in Southeast Asia in April 2006.

The application is the first step, and Eisai intends to apply in the nine other countries by September. In each case, Eisai will submit an application using data collected by Dainippon Sumitomo Pharma in clinical tests carried out in Japan.

The market for drugs to treat chronic gastritis is worth an estimated ¥1bn in the 10 countries of Southeast Asia for which Eisai holds the marketing rights to Gasmotin.

See more

You may also like

Regulatory

Alzheimer's drug lecanemab deemed unsuitable for the UK NHS by health regulator

Read more
The drug will not be available on the NHS owing to significant and potentially life-threatening side effects, as well as the cost of the medicine and its limited efficacy

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Alzheimer's drug lecanemab deemed unsuitable for the UK NHS by health regulator

The drug will not be available on the NHS owing to significant and potentially life-threatening side effects, as well as the cost of the medicine and its limited efficacy
Regulatory

FDA grants landmark approval for Alzheimer’s treatment

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory

AbbVie and Eisai launch online Humira support tool service

The free-of-charge service assists patients on Humira therapy by delivering support tools to their home or other requested location
Regulatory

Eisai and Merck combination cancer therapy approved by FDA

The approval for this population is based on results from a Phase III Study 309/KEYNOTE-775 trial
Ingredients

Therapeutics: lemborexant for sleep disorders

About a third of adults suffer from the symptoms of insomnia, such as difficulty falling asleep, staying asleep or both
Ingredients

AbbVie and Eisai obtain additional approval for Humira

The monoclonal antibody, Humira, is used in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis
Regulatory

Eisai enters into agreement with Adlai Nortye for potential anticancer agent

Eisai has entered a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisai's in-house discovered potential anticancer agent E7046, to Adlai Nortye Biopharma in all regions outside of Japan (excluding China)
Subscribe now